Safety and Immunogenicity of Tetanus Diphtheria and Acellular Pertussis (Tdap) Immunization During Pregnancy in Mothers and Infants: A Randomized Clinical Trial | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Vitek  CR, Pascual  FB, Baughman  AL, Murphy  TV.  Increase in deaths from pertussis among young infants in the United States in the 1990s.  Pediatr Infect Dis J. 2003;22(7):628-634.PubMedGoogle Scholar
2.
Healy  CM, Munoz  FM, Rench  MA, Halasa  NB, Edwards  KM, Baker  CJ.  Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum.  J Infect Dis. 2004;190(2):335-340.PubMedGoogle ScholarCrossref
3.
Gonik  B, Puder  KS, Gonik  N, Kruger  M.  Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants.  Infect Dis Obstet Gynecol. 2005;13(2):59-61.PubMedGoogle ScholarCrossref
4.
Van Savage  J, Decker  MD, Edwards  KM, Sell  SH, Karzon  DT.  Natural history of pertussis antibody in the infant and effect on vaccine response.  J Infect Dis. 1990;161(3):487-492.PubMedGoogle ScholarCrossref
5.
Broder  KR, Cortese  MM, Iskander  JK,  et al; Advisory Committee on Immunization Practices (ACIP).  Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2006;55(RR-3):1-34.PubMedGoogle Scholar
6.
Kretsinger  K, Broder  KR, Cortese  MM,  et al; Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee.  Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.  MMWR Recomm Rep. 2006;55(RR-17):1-37.PubMedGoogle Scholar
7.
Murphy  TV, Slade  BA, Broder  KR,  et al; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC).  Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Recomm Rep. 2008;57(26):723].  MMWR Recomm Rep. 2008;57(RR-4):1-51.PubMedGoogle Scholar
8.
Centers for Disease Control and Prevention (CDC).  Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months—Advisory Committee on Immunization Practices (ACIP), 2011.  MMWR Morb Mortal Wkly Rep. 2011;60(41):1424-1426.PubMedGoogle Scholar
9.
Centers for Disease Control and Prevention (CDC).  Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women—Advisory Committee on Immunization Practices (ACIP), 2012.  MMWR Morb Mortal Wkly Rep. 2013;62(7):131-135.PubMedGoogle Scholar
10.
Kapasi  A, Meade  BD, Plikaytis  B,  et al.  Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays.  Clin Vaccine Immunol. 2012;19(1):64-72.PubMedGoogle ScholarCrossref
11.
Klein  NP, Bartlett  J, Rowhani-Rahbar  A, Fireman  B, Baxter  R.  Waning protection after fifth dose of acellular pertussis vaccine in children.  N Engl J Med. 2012;367(11):1012-1019.PubMedGoogle ScholarCrossref
12.
Centers for Disease Control and Prevention.  Pertussis Surveillance Report. http://www.cdc.gov/pertussis/surv-reporting.html. Accessed June 30, 2013.
13.
Winter  K, Harriman  K, Zipprich  J,  et al.  California pertussis epidemic, 2010.  J Pediatr. 2012;161(6):1091-1096.PubMedGoogle ScholarCrossref
14.
Castagnini  LA, Healy  CM, Rench  MA, Wootton  SH, Munoz  FM, Baker  CJ.  Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection.  Clin Infect Dis. 2012;54(1):78-84.PubMedGoogle ScholarCrossref
15.
Halperin  BA, Morris  A, Mackinnon-Cameron  D,  et al.  Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women.  Clin Infect Dis. 2011;53(9):885-892.PubMedGoogle ScholarCrossref
16.
Zheteyeva  YA, Moro  PL, Tepper  NK,  et al.  Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women.  Am J Obstet Gynecol. 2012;207(1):e1-e7.PubMedGoogle ScholarCrossref
17.
 Abstracts of the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Chicago, Illinois, USA. August 14-17, 2011.  Pharmacoepidemiol Drug Saf. 2011;20(suppl 1):S1-S364.PubMedGoogle ScholarCrossref
18.
Gall  SA, Myers  J, Pichichero  M.  Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels.  Am J Obstet Gynecol. 2011;204(4):e1-e5.PubMedGoogle ScholarCrossref
19.
Taranger  J, Trollfors  B, Lagergård  T,  et al.  Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.  J Infect Dis. 2000;181(3):1010-1013.PubMedGoogle ScholarCrossref
20.
Heininger  U, Riffelmann  M, Bär  G, Rudin  C, von König  CH.  The protective role of maternally derived antibodies against Bordetella pertussis in young infants.  Pediatr Infect Dis J. 2013;32(6):695-698.PubMedGoogle ScholarCrossref
21.
Klein  NP, Bartlett  J, Fireman  B, Rowhani-Rahbar  A, Baxter  R.  Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers.  Pediatrics. 2013;131(6):e1716-e1722.PubMedGoogle ScholarCrossref
22.
Glezen  WP.  Effect of maternal antibodies on the infant immune response.  Vaccine. 2003;21(24):3389-3392.PubMedGoogle ScholarCrossref
23.
Englund  JA, Anderson  EL, Reed  GF,  et al.  The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.  Pediatrics. 1995;96(3, pt 2):580-584.PubMedGoogle Scholar
24.
Hardy-Fairbanks  AJ, Pan  SJ, Decker  MD,  et al.  Immune responses in infants whose mothers received Tdap vaccine during pregnancy.  Pediatr Infect Dis J. 2013;32(11):1257-1260.PubMedGoogle ScholarCrossref
Preliminary Communication
May 7, 2014

Safety and Immunogenicity of Tetanus Diphtheria and Acellular Pertussis (Tdap) Immunization During Pregnancy in Mothers and Infants: A Randomized Clinical Trial

Author Affiliations
  • 1Department of Pediatrics, Baylor College of Medicine, Houston, Texas
  • 2Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas
  • 3Woman’s OB/GYN Specialists, Houston, Texas
  • 4Private obstetric practice, Houston, Texas
  • 5Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, North Carolina
  • 6Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina
  • 7Group Health Research Institute, Seattle, Washington
  • 8Seattle Children’s Research Institute, Department of Pediatrics, University of Washington, Seattle
  • 9EMMES Corporation, Rockville, Maryland
JAMA. 2014;311(17):1760-1769. doi:10.1001/jama.2014.3633
Abstract

Importance  Maternal immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine could prevent infant pertussis.

Objective  To evaluate the safety and immunogenicity of Tdap immunization during pregnancy and its effect on infant responses to diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine.

Design, Setting, and Participants  Phase 1-2, randomized, double-blind, placebo-controlled, clinical trial conducted from 2008 to 2012. Forty-eight pregnant women aged 18 to 45 years received Tdap (n = 33) or placebo (n = 15) at 30 to 32 weeks’ gestation, with crossover immunization postpartum.

Interventions  Tdap vaccination at 30 to 32 weeks’ gestation or postpartum.

Main Outcomes and Measures  Primary outcomes were maternal and infant adverse events, pertussis illness, and infant growth and development until age 13 months. Secondary outcomes were antibody concentrations in pregnant women before and 4 weeks after Tdap immunization or placebo, at delivery and 2 months’ postpartum, and in infants at birth, at 2 months, and after the third and fourth doses of DTaP.

Results  No Tdap-associated serious adverse events occurred in women or infants. Injection site reactions after Tdap immunization were reported in 26 (78.8% [95% CI, 61.1%-91.0%]) and 12 (80% [95% CI, 51.9%-95.7%]) pregnant and postpartum women, respectively (P > .99). Systemic symptoms were reported in 12 (36.4% [ 95% CI, 20.4%-54.9%]) and 11 (73.3% [95% CI, 44.9%-92.2%]) pregnant and postpartum women, respectively (P = .03). Growth and development were similar in both infant groups. No cases of pertussis occurred. Significantly higher concentrations of pertussis antibodies were measured at delivery in women who received Tdap during pregnancy vs postpartum (eg, pertussis toxin antibodies: 51.0 EU/mL [95% CI, 37.1-70.1] and 9.1 EU/mL [95% CI, 4.6-17.8], respectively; P < .001) and in their infants at birth (68.8 EU/mL [95% CI, 52.1-90.8] and 14.0 EU/mL [95% CI, 7.3-26.9], respectively; P < .001) and at age 2 months (20.6 EU/mL [95% CI, 14.4-29.6] and 5.3 EU/mL [95% CI, 3.0-9.4], respectively; P < .001). Antibody responses in infants born to women receiving Tdap during pregnancy were not different following the fourth dose of DTaP.

Conclusions and Relevance  This preliminary assessment did not find an increased risk of adverse events among women who received Tdap vaccine during pregnancy or their infants. For secondary outcomes, maternal immunization with Tdap resulted in high concentrations of pertussis antibodies in infants during the first 2 months of life and did not substantially alter infant responses to DTaP. Further research is needed to provide definitive evidence of the safety and efficacy of Tdap immunization during pregnancy.

Trial Registration  clinicaltrials.gov Identifier: NCT00707148

×